• 1
    Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev 2007; 6: 5203.
  • 2
    Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006; 5: 1258.
  • 3
    Maeda M, Matubara K, Hirano H, Watabe H, Ichiki Y, Mori S. Pitting scars in progressive systemic sclerosis. Dermatology 1993; 187: 1048.
  • 4
    Denton C, Korn J. Digital ulceration and critical digital ischemia in scleroderma. Scleroderma Care Res 2003; 1: 126.
  • 5
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 398593.
  • 6
    Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 26977.
  • 7
    Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32: 12738.
  • 8
    Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 56977.
  • 9
    MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 4539.
  • 10
    Plastiras SC, Karadimitrakis SP, Kampolis C, Moutsopoulos HM, Tzelepis GE. Determinants of pulmonary hypertension in scleroderma. Semin Arthritis Rheum 2007; 36: 3926.
  • 11
    Sunderkotter C, Herrgott I, Bruckner C, Moinzadeh P, Pfeiffer C, Gerss J, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009; 160: 83543.
  • 12
    Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine (Baltimore) 1980; 59: 393408.
  • 13
    Tiev KP, Diot E, Clerson P, Dupuis-Simeon F, Hachulla E, Hatron PY, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinerAIR-Sclerodermie). J Rheumatol 2009; 36: 14706.
  • 14
    Akesson A, Fiori G, Krieg T, van den Hoogen FH, Seibold JR. Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 2003; 21 Suppl 29: S58.
  • 15
    Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9: 78993.
  • 16
    Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39: 68291.
  • 17
    Ostojic P, Damjanov N, Pavlov-Dolijanovic S, Radunovic G. Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease. Clin Hemorheol Microcirc 2004; 31: 2815.
  • 18
    Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998; 25: 4626.
  • 19
    Salojin KV, Le Tonqueze M, Saraux A, Nassonov EL, Dueymes M, Piette JC, et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997; 102: 17885.
  • 20
    Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Meroni PL, Del Papa N, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998; 16: 52732.
  • 21
    Salozhin KV, Shcherbakov AB, Nasonov EL, Kolesova NV, Romanov I, Guseva NG. Antiendothelial antibodies in systemic scleroderma and Raynaud's disease. Ter Arkh 1995; 67: 547. In Russian.
  • 22
    Mouthon L, Mestre-Stanislas C, Berezne A, Rannou F, Guilpain P, Revel M, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2009; 69: 2147.
  • 23
    Hanke K, Dahnrich C, Bruckner CS, Huscher D, Becker M, Jansen A, et al. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009; 1: R28.
  • 24
    Herrick AL, Roberts C, Tracey A, Silman A, Anderson M, Goodfield M, et al. Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis Rheum 2009; 60: 87882.